Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Incyte Corp.

www.incyte.com

Latest From Incyte Corp.

Bristol Engineers An Oral TYK2 Inhibitor With Biologic-Like Efficacy That Rivals JAK Safety

The company's first set of Phase II data for its oral, selective TYK2 inhibitor in psoriasis showed a consistent dose response as well as safety that could rival the related JAK inhibitor class. BMS-986165 already is in Phase III for psoriasis; it's in Phase II for lupus and Crohn's disease.

Clinical Trials Drug Safety

US FDA’s Latest Breakthrough Therapy Awards Include Asthma, Alopecia Areata, And (Of Course) Oncology Therapies

New BTDs include Loxo’s RET inhibitor for RET fusion-positive lung cancer and RET mutant medullary thyroid cancer, Y-mAbs’ naxitamab for high-risk neuroblastoma, AstraZeneca/Amgen’s tezepelumab for severe asthma, and Pfizer’s JAK3 inhibitor for alopecia areata.
Drug Review Review Pathway

Gilead/Galapagos' Trailing JAK1 Filgotinib Boosted By AS Trial

Gilead and Galapagos have more decent clinical data for filgotinib tucked under their belt as the JAK1 inhibitor shows benefit in another indication, ankylosing spondylitis, with a safety profile that remains reassuring.

Clinical Trials Inflammation

Medicare Advisers Endorse Patient Reported Outcomes For CAR-T With Caveats

Medicare Evidence Development and Coverage Advisory Committee votes that four existing tools are valid and could be “generalizable” to Medicare beneficiaries.
Medicare Reimbursement
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Immune Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Incyte Pharmaceuticals Inc.
  • Incyte Genomics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Incyte Corp.
  • Senior Management
  • Hervé A Hoppenot, MD, Pres. & CEO
    David W Gryska, EVP, CFO
    Reid M Huber, PhD, EVP, CSO
    Vijay Iyengar, MD, EVP, Global Strategy & Corp. Dev.
    Steven H Stein, MD, EVP, CMO
  • Contact Info
  • Incyte Corp.
    Phone: (302) 498-6700
    1801 Augustine Cut-Off
    Wilmington, DE 19803
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register